ALX Oncology Announces Updated Data from Ongoing Clinical Trial (ASPEN-01) of Evorpacept Showing Emerging Clinical Benefit in Survival-Based Endpoints in Patients with Advanced Solid Tumors

Pat Purcell
Meeting Engagement

Joey Cohen
Medication Adherence

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability

Suma Ramadas, PhD
Medical Affairs

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

David Linetsky
Point-of-Care Marketing

Liz Kane
Impactful Strategy

Brenda Snow
Authentic Patient Voice